Trial Profile
A Randomized, Double-Blind, Active Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination BMS-201038 (AEGR-733) and Ezetimibe vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Lomitapide (Primary) ; Ezetimibe
- Indications Hypercholesterolaemia; Lipid metabolism disorders
- Focus Therapeutic Use
- Sponsors Aegerion Pharmaceuticals
- 17 Jun 2009 Final results presented at the American Diabetes Association's 69th Scientific Sessions (7 June) and the International Symposium on Atherosclerosis (15 Jun).
- 08 Nov 2008 Results reported at the 81st Annual Scientific Sessions of the American Heart Association.
- 04 Oct 2007 Results have been presented.